Structure Therapeutics(us:GPCR)
17.31
-12.44%
Updated on 2025-03-31
Open:19.13
Close:17.31
High:19.13
Low:17.25
Prev Close:19.77
Volume:1.21M
Turnover:21.38M
Turnover Ratio:2.11%
Shares:57.34M
MarketCap:992.60M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 177 | 59371838 | 103.80% | 60 | 63 | 45 |
| 2024-03-31 | 143 | 43639591 | 93.61% | 24 | 46 | 59 |
| 2023-12-31 | 138 | 42677167 | 91.96% | 54 | 37 | 41 |
| 2023-09-30 | 90 | 32794287 | 85.45% | 42 | 29 | 12 |
| 2023-06-30 | 52 | 17647287 | 46.12% | 14 | 11 | 14 |
| 2023-03-31 | 38 | 14758878 | 38.59% | 38 | 0 | 0 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Wellington Management Group Llp | 5827656 | 12.50% | 1455330 | 33.28% |
| 2024-03-31 | Fmr Llc | 2948764 | 6.33% | -1085820 | -26.91% |
| 2024-03-31 | Driehaus Capital Management Llc | 2490303 | 5.34% | -108776 | -4.18% |
| 2024-03-31 | Federated Hermes, Inc. | 2257206 | 4.84% | -10000 | -0.44% |
| 2024-03-31 | Janus Henderson Group Plc | 2076700 | 4.45% | 532284 | 34.47% |
| 2024-03-31 | Tcg Crossover Management, Llc | 1598421 | 3.43% | -511163 | -24.23% |
| 2024-03-31 | Price T Rowe Associates Inc /Md/ | 1560950 | 3.35% | -118486 | -7.05% |
| 2024-03-31 | Capital Research Global Investors | 1527483 | 3.28% | 553948 | 56.90% |
| 2024-03-31 | Ra Capital Management, L.P. | 1510362 | 3.24% | 1023530 | 210.24% |
| 2024-03-31 | Alyeska Investment Group, L.P. | 1300986 | 2.79% | 1122309 | 628.12% |
About
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Address:601 Gateway Boulevard,Suite 900
Website:http://www.structuretx.com
Market Movers